Search alternatives:
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
mm decrease » _ decrease (Expand Search), nn decrease (Expand Search), gy decreased (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
501
Decreased capillary density and cardiac fibrosis in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> heart.
Published 2013“…Capillary density was decreased in <i>Nkx2.5-Cre/Foxm1<sup>fl/fl</sup></i> hearts at P11 (A–B, I), while coronary vessel formation was not altered (C–D). …”
-
502
-
503
-
504
CNP decrease mitochondrial membrane potential and induce mitochondrial fragmentation in melanoma cells.
Published 2020“…<p>A, 300 μM CNP (4 h) significantly decreased mitochondrial membrane potential in A375 cells, but not in melanocytes, indicated by changes of TMRM dependent fluorescence in mitochondria. …”
-
505
SPL treatment decreases diabetes-induced decrement in protein expression of cldn-5 in glomeruli (GL) and cldn-2 and occldn in proximal tubules (PT).
Published 2017“…<p>SPL prevents diabetes-induced decrease of cldn-5 protein expression (A and B) in GL, and mRNA (F) and protein expression of cldn-2 (A and C), and protein expression of occldn (A and D) in PT (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0177362#pone.0177362.s002" target="_blank">S2 Fig</a>). …”
-
506
SUVmax and SUVmean for each hot sphere when the Gaussian filter is changed.
Published 2025Subjects: -
507
-
508
-
509
-
510
-
511
-
512
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
513
-
514
-
515
-
516
ku0063794 but not rapamycin decreased the TRPC6 mRNA levels in podocytes.
Published 2014“…<p>(A) ku0063794 (2 µmol/l) or rapamycin (50 nmol/l) was applied to evaluate the effects of mTORC1 and mTORC2 on TRPC6 in podocytes. …”
-
517
-
518
-
519
-
520